{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T13:14:16Z","timestamp":1773753256721,"version":"3.50.1"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,1,29]],"date-time":"2010-01-29T00:00:00Z","timestamp":1264723200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Gastroenterol Rep"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1007\/s11894-009-0079-2","type":"journal-article","created":{"date-parts":[[2010,1,28]],"date-time":"2010-01-28T06:02:47Z","timestamp":1264658567000},"page":"13-22","source":"Crossref","is-referenced-by-count":18,"title":["Latest and Emerging Therapies for Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis"],"prefix":"10.1007","volume":"12","author":[{"given":"Claudia O.","family":"Zein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith D.","family":"Lindor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,1,29]]},"reference":[{"key":"79_CR1","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJMra043898","volume":"353","author":"MM Kaplan","year":"2005","unstructured":"Kaplan MM, Gershwin ME: Primary biliary cirrhosis. N Engl J Med 2005, 353:1261\u20131274.","journal-title":"N Engl J Med"},{"key":"79_CR2","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1089-3261(03)00102-8","volume":"7","author":"MI Prince","year":"2003","unstructured":"Prince MI, James OF: The epidemiology of primary biliary cirrhosis. Clin Liver Dis 2003, 7:795\u2013819.","journal-title":"Clin Liver Dis"},{"key":"79_CR3","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/hep.20907","volume":"42","author":"ME Gershwin","year":"2005","unstructured":"Gershwin ME, Selmi C, Worman HJ, et al.: Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology 2005, 42:1194\u20131202.","journal-title":"Hepatology"},{"key":"79_CR4","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1172\/JCI0214698","volume":"109","author":"H Kita","year":"2002","unstructured":"Kita H, Matsumura S, He XS, et al.: Quantitative and functional analysis of PDC-E2\u2013specific autoreactive cytotoxic T lymphocytes in primary biliary cirrhosis. J Clin Invest 2002, 109:1231\u20131240.","journal-title":"J Clin Invest"},{"key":"79_CR5","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1053\/gast.2002.36027","volume":"123","author":"M Prince","year":"2002","unstructured":"Prince M, Chetwynd A, Newman W, et al.: Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28\u00a0years. Gastroenterology 2002, 123:1044\u20131051.","journal-title":"Gastroenterology"},{"key":"79_CR6","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1053\/cgh.2003.50014","volume":"1","author":"CO Zein","year":"2003","unstructured":"Zein CO, Angulo P, Lindor KD: When is liver biopsy needed in the diagnosis of primary biliary cirrhosis. Clin Gastroenterol Hepatol 2003, 1:89\u201395.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"79_CR7","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/hep.22906","volume":"50","author":"KD Lindor","year":"2009","unstructured":"\u2022 Lindor KD, Gershwin ME, Poupon R, et al.: AASLD practice guidelines. Primary biliary cirrhosis. Hepatology 2009, 50:291\u2013308. These guidelines are an excellent review of crucial published data and recommendations for the evaluation and management of patients with PBC.","journal-title":"Hepatology"},{"key":"79_CR8","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S0168-8278(99)80136-6","volume":"30","author":"P Angulo","year":"1999","unstructured":"Angulo P, Dickson ER, Therneau TM, et al.: Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. J Hepatol 1999, 30:830\u2013835.","journal-title":"J Hepatol"},{"key":"79_CR9","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1053\/gast.1996.v110.pm8613058","volume":"110","author":"KD Lindor","year":"1996","unstructured":"Lindor KD, Therneau TM, Jorgensen RA, et al.: Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. Gastroenterology 1996, 110:1515\u20131518.","journal-title":"Gastroenterology"},{"key":"79_CR10","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/0016-5085(94)90021-3","volume":"106","author":"KD Lindor","year":"1994","unstructured":"Lindor KD, Dickson ER, Baldus WP, et al.: Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994, 106:1284\u20131290.","journal-title":"Gastroenterology"},{"key":"79_CR11","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/hep.1840190512","volume":"19","author":"EJ Heathcote","year":"1994","unstructured":"Heathcote EJ, Cauch-Dukek K, Walker V, et al.: The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994, 19:1149\u20131156.","journal-title":"Hepatology"},{"key":"79_CR12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/hep.510290116","volume":"29","author":"T Pasha","year":"1999","unstructured":"Pasha T, Heathcote J, Gabriel S, et al.: Cost-effectiveness of ursodeoxycholic acid therapy in primary biliary cirrhosis. Hepatology 1999, 29:21\u201326.","journal-title":"Hepatology"},{"key":"79_CR13","first-page":"759","volume":"22","author":"B Combes","year":"1995","unstructured":"Combes B, Carithers RL Jr, Maddrey WC, et al.: A randomized, double blind, placebo controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995, 22:759\u2013766.","journal-title":"Hepatology"},{"key":"79_CR14","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1572-0241.2004.04047.x","volume":"99","author":"B Combes","year":"2004","unstructured":"Combes B, Luketic VA, Peters MG, et al.: Prolonged follow-up of patients in the US multicenter trial of ursodeoxycholic acid for primary biliary cirrhosis. Am J Gastroenterol 2004, 99:264\u2013268.","journal-title":"Am J Gastroenterol"},{"key":"79_CR15","doi-asserted-by":"crossref","unstructured":"Poupon RE, Balkau B, Eschw\u00e8ge E, et al.: A multicenter, controlled trial of ursodiol for treatment of primary biliary cirrhosis. UDCA-PBC study group. N Engl J Med 1991, 324: 1548\u20131554.","DOI":"10.1056\/NEJM199105303242204"},{"key":"79_CR16","doi-asserted-by":"crossref","unstructured":"Poupon RE, Poupon R, Balkau B: Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC study group. N Engl J Med 1994, 330:1342\u20131347.","DOI":"10.1056\/NEJM199405123301903"},{"key":"79_CR17","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0168-8278(00)80216-0","volume":"32","author":"A Pares","year":"2000","unstructured":"Pares A, Caballeria L, Rodes J, et al.: Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver. J Hepatology 2000, 32:561\u2013566.","journal-title":"J Hepatology"},{"key":"79_CR18","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","volume":"130","author":"A Pares","year":"2006","unstructured":"Pares A, Caballeria L, Rodes J: Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 2006, 130:715\u2013720.","journal-title":"Gastroenterology"},{"key":"79_CR19","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1136\/gut.36.6.935","volume":"36","author":"RA Jorgensen","year":"1995","unstructured":"Jorgensen RA, Dickson ER, Hoffman AF, et al.: Characterization of patients with a complete biochemical response to ursodeoxycholic acid. Gut 1995, 36:935\u2013938.","journal-title":"Gut"},{"key":"79_CR20","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.22428","volume":"48","author":"C Corpechot","year":"2008","unstructured":"\u2022 Corpechot C, Abenavoli L, Rabahi N, et al.: Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 2008, 48:871\u2013877. This article presents important results regarding the biochemical response to UDCA as a predictor of survival in patients with PBC.","journal-title":"Hepatology"},{"key":"79_CR21","doi-asserted-by":"crossref","unstructured":"\u2022 Kuiper EM, Hansen BE, deVries RA, et al.: Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology 2009, 136:1281\u20131287. This article discusses the largest study assessing the best predictors of survival of PBC patients based on biochemical response to UDCA therapy.","DOI":"10.1053\/j.gastro.2009.01.003"},{"key":"79_CR22","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1002\/hep.510290603","volume":"29","author":"RE Poupon","year":"1999","unstructured":"Poupon RE, Bonnand AM, Chretien Y, et al.: Ten-year survival in ursodeoxycholic acid treated patients with primary biliary cirrhosis. The UDCA-PBC study group. Hepatology 1999, 29:1668\u20131671.","journal-title":"Hepatology"},{"key":"79_CR23","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3748\/wjg.v10.i6.894","volume":"10","author":"K Dohmen","year":"2004","unstructured":"Dohmen K, Mizuta T, Nakamuta M, et al.: Fenofibrate for patients with asymptomatic primary biliary cirrosis. World J Gastroenterol 2004, 10:894\u2013898.","journal-title":"World J Gastroenterol"},{"key":"79_CR24","doi-asserted-by":"crossref","unstructured":"Mason AL, Lindor KD, Bacon BR, et al.: Randomized controlled trial of zidovudine and lamivudine in patients with primary biliary cirrhosis stabilized on ursodiol. Aliment Pharmacol Ther 2008 (Epub ahead of print).","DOI":"10.1111\/j.1365-2036.2008.03799.x"},{"key":"79_CR25","first-page":"550A","volume":"46","author":"RP Myers","year":"2007","unstructured":"Myers RP, Shaheen AA, Swain MG, et al.: Rituximab for primary biliary cirrhosis (PBC) refractory to ursodeoxycholic acid (UDCA). Hepatology 2007, 46:550A.","journal-title":"Hepatology"},{"key":"79_CR26","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/hep.21229","volume":"44","author":"R Poupon","year":"2006","unstructured":"Poupon R, Chazouilleres O, Corpechot C, et al.: Development of autoimmune hepatitis in typical primary biliary cirrhosis. Hepatology 2006, 44:85\u201390.","journal-title":"Hepatology"},{"key":"79_CR27","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1111\/j.1572-0241.2007.01136.x","volume":"102","author":"MG Silveira","year":"2007","unstructured":"Silveira MG, Talwalkar JA, Angulo P, et al.: Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes. Am J Gastroenterol 2007, 102:1244\u20131250.","journal-title":"Am J Gastroenterol"},{"key":"79_CR28","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jhep.2005.10.017","volume":"44","author":"O Chazouilleres","year":"2006","unstructured":"Chazouilleres O, Wendum D, Serfaty L, et al.: Long-term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. J Hepatol 2006, 44:400\u2013406.","journal-title":"J Hepatol"},{"key":"79_CR29","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/hep.21337","volume":"44","author":"NF LaRusso","year":"2006","unstructured":"LaRusso NF, Shneider BL, Black D, et al.: Primary sclerosing cholangitis: summary of a workshop. Hepatology 2006, 44:746\u2013764.","journal-title":"Hepatology"},{"key":"79_CR30","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jhep.2004.10.011","volume":"42","author":"A Bergquist","year":"2005","unstructured":"Bergquist A, Lindberg G, Saarinen S, et al.: Increased prevalence of primary sclerosing cholangitis among first degree relatives. J Hepatol 2005, 42:252\u2013256.","journal-title":"J Hepatol"},{"key":"79_CR31","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.autrev.2004.09.003","volume":"4","author":"CA Aoki","year":"2005","unstructured":"Aoki CA, Bowlus CL, Gershwin ME: The immunobiology of primary sclerosing cholangitis. Autoimmun Rev 2005, 4:137\u2013143.","journal-title":"Autoimmun Rev"},{"key":"79_CR32","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.3748\/wjg.14.3781","volume":"14","author":"JR Hov","year":"2008","unstructured":"Hov JR, Boberg KM, Karlsen TH: Autoantibodies in primary sclerosing cholangitis. World J Gastroenterol 2008, 14:3781\u20133791.","journal-title":"World J Gastroenterol"},{"key":"79_CR33","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.cgh.2005.10.007","volume":"4","author":"AE Berstad","year":"2006","unstructured":"Berstad AE, Aabakken L, Smith HJ, et al.: Diagnostic accuracy of magnetic resonance and endoscopic retrograde cholangiography in primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2006, 4:514\u2013520.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"79_CR34","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11894-009-0006-6","volume":"11","author":"E Bjornsson","year":"2009","unstructured":"Bjornsson E: Small-duct primary sclerosing cholangitis. Curr Gastroenterol Rep 2009, 11:37\u201341.","journal-title":"Curr Gastroenterol Rep"},{"key":"79_CR35","doi-asserted-by":"crossref","unstructured":"Lindor KD: Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997, 336:691\u2013695.","DOI":"10.1056\/NEJM199703063361003"},{"key":"79_CR36","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/hep.20370","volume":"40","author":"D Rost","year":"2004","unstructured":"Rost D, Rudolph G, Kloeters-Plachky P, et al.: Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis. Hepatology 2004, 40:693\u2013698.","journal-title":"Hepatology"},{"key":"79_CR37","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1053\/gast.2001.27965","volume":"121","author":"SA Mitchell","year":"2001","unstructured":"Mitchell SA, Bansi DS, Hunt N, et al.: A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001, 121:900\u2013907.","journal-title":"Gastroenterology"},{"key":"79_CR38","doi-asserted-by":"crossref","unstructured":"Olsson R, Boberg KM, deMuckadell OS, et al.: High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 2005, 129:1464\u20131472.","DOI":"10.1053\/j.gastro.2005.08.017"},{"key":"79_CR39","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1111\/j.1572-0241.2001.03777.x","volume":"96","author":"DM Harnois","year":"2001","unstructured":"Harnois DM, Angulo P, Jorgensen RA, et al.: High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol 2001, 96:1558\u20131562.","journal-title":"Am J Gastroenterol"},{"key":"79_CR40","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jhep.2007.12.023","volume":"48","author":"SN Cullen","year":"2008","unstructured":"Cullen SN, Rust C, Fleming K, et al.: High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. J Hepatol 2008, 48:792\u2013800.","journal-title":"J Hepatol"},{"key":"79_CR41","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/hep.23174","volume":"50","author":"KD Lindor","year":"2009","unstructured":"\u2022 Lindor KD, Enders FB, Schmoll JA, et al.: Randomized, double blind controlled trial of high dose ursodeoxycholic acid for primary sclerosing cholangitis. Hepatology 2009, 50:671\u2013673. The results of this randomized controlled trial support the conclusion that high-dose UDCA at 28 to 30\u00a0mg\/kd\/d should not be used in patients with PSC given the lack of survival benefits and higher risk of adverse events.","journal-title":"Hepatology"},{"key":"79_CR42","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1053\/gast.2003.50156","volume":"124","author":"DS Pardi","year":"2003","unstructured":"Pardi DS, Loftus EV, Kremers WK, et al.: Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003, 124:889\u2013893.","journal-title":"Gastroenterology"},{"key":"79_CR43","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1478-3231.2007.01441.x","volume":"27","author":"JA Talwalkar","year":"2007","unstructured":"Talwalkar JA, Gossard AA, Keach JC, et al.: Tacrolimus for the treatment of primary sclerosing cholangitis. Liver Int 2007, 27:451\u2013453.","journal-title":"Liver Int"},{"key":"79_CR44","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/hep.20457","volume":"40","author":"M Farkkila","year":"2004","unstructured":"Farkkila M, Karvonen AL, Nurmi H, et al.: Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Hepatology 2004, 40:1379\u20131386.","journal-title":"Hepatology"},{"key":"79_CR45","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/ajg.2008.14","volume":"104","author":"MG Silveria","year":"2009","unstructured":"Silveria MG, Torok NJ, Gossard AA, et al.: Minocycline in the treatment of patients with primary sclerosing cholangitis: results of a pilot study. Am J Gastroenterol 2009, 104:83\u201388.","journal-title":"Am J Gastroenterol"},{"key":"79_CR46","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1007\/s10620-007-0052-6","volume":"53","author":"P Angulo","year":"2008","unstructured":"Angulo P, Jorgensen RA, Kowdley KV, et al.: Silymarin in the treatment of patients with primary sclerosing cholangitis: an open label pilot study. Dig Dis Sci 2008, 53:1716\u20131720.","journal-title":"Dig Dis Sci"},{"key":"79_CR47","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s00535-006-1831-0","volume":"41","author":"R Kita","year":"2006","unstructured":"Kita R, Takamatsu S, Kimura T, et al.: Bezafibrate may attenuate biliary damage associated with chronic liver diseases accompanied by high serum biliary enzyme levels. J Gastroenterol 2006, 41:686\u2013692.","journal-title":"J Gastroenterol"},{"key":"79_CR48","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/00042737-200406000-00012","volume":"16","author":"L Gheorge","year":"2004","unstructured":"Gheorge L, Iacob S, Gheorghe C, et al.: Frequency and predictive factors for overlap syndrome between autoimmune hepatitis and primary cholestatic liver disease. Eur J Gastroenterol Hepatol 2004, 16:585\u2013592.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"79_CR49","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1111\/j.1572-0241.2005.41841.x","volume":"100","author":"A Floreani","year":"2005","unstructured":"Floreani A, Rizzotto ER, Ferrara F, et al.: Clinical course and outcome of autoimmune hepatitis\/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol 2005, 100:1516\u20131522.","journal-title":"Am J Gastroenterol"},{"key":"79_CR50","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1053\/j.gastro.2008.01.042","volume":"134","author":"E Bjornsson","year":"2008","unstructured":"Bjornsson E, Olsson R, Bergquist A, et al.: The natural history of small-duct primary sclerosing cholangitis. Gastroenterology 2008, 134:975\u2013980.","journal-title":"Gastroenterology"},{"key":"79_CR51","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/hep.21960","volume":"47","author":"P Charatcharoenwitthaya","year":"2008","unstructured":"Charatcharoenwitthaya P, Angulo P, Enders FB, et al.: Impact of inflammatory bowel disease and ursodeoxycholic acid therapy of small duct primary sclerosing cholangitis. Hepatology 2008, 47:133\u2013142.","journal-title":"Hepatology"},{"key":"79_CR52","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1053\/j.gastro.2007.12.009","volume":"134","author":"A Ghazale","year":"2008","unstructured":"Ghazale A, Chari ST, Zhang L, et al.: Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology 2008, 134:706\u2013715.","journal-title":"Gastroenterology"},{"key":"79_CR53","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1111\/j.1572-0241.2006.00772.x","volume":"101","author":"FD Mendes","year":"2006","unstructured":"Mendes FD, Jorgensen R, Keach J, et al.: Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol 2006, 101:2070\u20132075.","journal-title":"Am J Gastroenterol"},{"key":"79_CR54","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1572-0241.2004.04067.x","volume":"99","author":"K Burak","year":"2004","unstructured":"Burak K, Angulo P, Pasha T, et al.: Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 2004, 99:523\u2013526.","journal-title":"Am J Gastroenterol"},{"key":"79_CR55","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1007\/s10620-005-2927-8","volume":"50","author":"C Levy","year":"2005","unstructured":"Levy C, Lymp J, Angulo P, et al.: The value of CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci 2005, 50:1734\u20131740.","journal-title":"Dig Dis Sci"},{"key":"79_CR56","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/hep.22441","volume":"48","author":"P Charatcharoenwithaya","year":"2008","unstructured":"Charatcharoenwithaya P, Enders FB, Halling KC, et al.: Utility of serum markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology 2008, 48:1106\u20131117.","journal-title":"Hepatology"},{"key":"79_CR57","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/01.sla.0000179678.13285.fa","volume":"242","author":"DJ Rea","year":"2005","unstructured":"Rea DJ, Hemback JK, Rosen CB, et al.: Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 2005, 242:451\u2013458.","journal-title":"Ann Surg"},{"key":"79_CR58","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/hep.21230","volume":"44","author":"JS Newton","year":"2006","unstructured":"Newton JS, Gibson GJ, Tomlinson M, et al.: Fatigue in primary biliary cirrhosis is associated with excessive daytime somnolence. Hepatology 2006, 44:91\u201398.","journal-title":"Hepatology"},{"key":"79_CR59","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1365-2036.2006.03223.x","volume":"25","author":"DE Jones","year":"2007","unstructured":"Jones DE, Newton JL: An open study of modafinil for the treatment of daytime somnolence and fatigue in primary biliary cirrhosis. Aliment Pharmacol Ther 2007, 25:471\u2013476.","journal-title":"Aliment Pharmacol Ther"},{"key":"79_CR60","doi-asserted-by":"crossref","unstructured":"Ian Gan S, de Jongh M, Kaplan MM: Modafinil in the treatment of debilitating fatigue in primary biliary cirrhosis: a clinical experience. Dig Dis Sci 2009, 54:2242\u20132246.","DOI":"10.1007\/s10620-008-0613-3"},{"key":"79_CR61","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/j.1478-3231.2006.01326.x","volume":"26","author":"S Khurana","year":"2006","unstructured":"Khurana S, Singh P: Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized controlled trials. Liver Int 2006, 26:943\u2013948.","journal-title":"Liver Int"},{"key":"79_CR62","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/hep.21553","volume":"45","author":"MJ Mayo","year":"2007","unstructured":"Mayo MJ, Handem I, Saldana S, et al.: Sertraline as a first-line treatment for cholestatic pruritus. Hepatology 2007, 45:666\u2013674.","journal-title":"Hepatology"},{"key":"79_CR63","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1111\/j.1572-0241.2007.01200.x","volume":"102","author":"P Tandon","year":"2007","unstructured":"Tandon P, Rowe BH, Vandermeer B: The efficacy and safety of bile acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus. Am J Gastroenterol 2007, 102:1528\u20131536.","journal-title":"Am J Gastroenterol"},{"key":"79_CR64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1023\/B:DDAS.0000011827.87103.2e","volume":"49","author":"MP Epstein","year":"2004","unstructured":"Epstein MP, Kaplan MM: A pilot study of etanercept in the treatment of primary sclerosing cholangitis. Dig Dis Sci 2004, 49:1\u20134.","journal-title":"Dig Dis Sci"},{"key":"79_CR65","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/j.1572-0241.2004.30204.x","volume":"99","author":"A Pares","year":"2004","unstructured":"Pares A, Cisneros L, Salmeron JM, et al.: Extracorporeal albumin dialysis: a procedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol 2004, 99:1105\u20131110.","journal-title":"Am J Gastroenterol"},{"key":"79_CR66","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.jhep.2006.08.008","volume":"45","author":"T Pusl","year":"2006","unstructured":"Pusl T, Denk GU, Parhofer KG, et al.: Plasma separation and anion adsorption transiently relieve intractable pruritus in primary biliary cirrhosis. J Hepatol 2006, 45:887\u2013891.","journal-title":"J Hepatol"},{"key":"79_CR67","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S0168-8278(01)00144-1","volume":"35","author":"KV Menon","year":"2001","unstructured":"Menon KV, Angulo P, Weston S, et al.: Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. J Hepatol 2001, 35:316\u2013323.","journal-title":"J Hepatol"},{"key":"79_CR68","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0168-8278(98)80253-5","volume":"29","author":"P Angulo","year":"1998","unstructured":"Angulo P, Therneau TM, Jorgensen A, et al.: Bone disease in patients with primary sclerosing cholangitis: prevalence, severity, and prediction of progression. J Hepatol 1998, 29:729\u2013735.","journal-title":"J Hepatol"},{"key":"79_CR69","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2009.04.009","volume":"51","author":"European Association for the Study of the Liver","year":"2009","unstructured":"European Association for the Study of the Liver: EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol 2009, 51:237\u2013267.","journal-title":"J Hepatol"},{"key":"79_CR70","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/hep.20866","volume":"42","author":"CO Zein","year":"2005","unstructured":"Zein CO, Jorgensen RA, Clarke B, et al.: Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. Hepatology 2005, 42:762\u2013771.","journal-title":"Hepatology"},{"key":"79_CR71","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/00004836-199504000-00011","volume":"20","author":"RA Jorgensen","year":"1995","unstructured":"Jorgensen RA, Lindor KD, Sartin JS, et al.: Serum lipid and fat-soluble vitamin levels in primary sclerosing cholangitis. J Clin Gastroenterol 1995, 20:215\u2013219.","journal-title":"J Clin Gastroenterol"},{"key":"79_CR72","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1111\/j.1572-0241.2001.04134.x","volume":"96","author":"JR Phillips","year":"2001","unstructured":"Phillips JR, Angulo P, Petterson T, et al.: Fat-soluble vitamin levels in patients with primary biliary cirrhosis. Am J Gastroenterol 2001, 96:2745\u20132750.","journal-title":"Am J Gastroenterol"},{"key":"79_CR73","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/hep.20933","volume":"42","author":"J Bruix","year":"2005","unstructured":"Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma. Hepatology 2005, 42:1208\u20131236.","journal-title":"Hepatology"},{"key":"79_CR74","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1002\/hep.21907","volume":"46","author":"G Garcia-Tsao","year":"2007","unstructured":"Garcia-Tsao G, Sanya AJ, Grace ND, et al.: Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007, 46:922\u2013938.","journal-title":"Hepatology"},{"key":"79_CR75","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/hep.20029","volume":"39","author":"CO Zein","year":"2004","unstructured":"Zein CO, Angulo P, Lindor KD: Prevalence and predictors of esophageal varices in primary sclerosing cholangitis. Hepatology 2004, 39:204\u2013210.","journal-title":"Hepatology"},{"key":"79_CR76","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1478-3231.1999.tb00020.x","volume":"19","author":"P Angulo","year":"1999","unstructured":"Angulo P, Lindor KD, Therneau TM, et al.: Utilization of the Mayo Risk Score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid. Liver 1999, 19:115\u2013121.","journal-title":"Liver"},{"key":"79_CR77","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.cgh.2007.02.031","volume":"5","author":"C Levy","year":"2007","unstructured":"Levy C, Zein CO, Gomez J, et al.: Prevalence and predictors of esophageal varices in patients with primary biliary cirrhosis. Clin Gastroenterol Hepatol 2007, 5:803\u2013808.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"79_CR78","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1136\/gut.2004.040832","volume":"54","author":"B Bessler","year":"2005","unstructured":"Bessler B, Pinto R, El-Ashry D, et al.: Which patients with primary biliary cirrhosis or primary sclerosing cholangitis should undergo endoscopic screening for esophageal varices detection? Gut 2005, 54:407\u2013410.","journal-title":"Gut"}],"container-title":["Current Gastroenterology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-009-0079-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11894-009-0079-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-009-0079-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T00:40:19Z","timestamp":1634776819000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11894-009-0079-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1,29]]},"references-count":78,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["79"],"URL":"https:\/\/doi.org\/10.1007\/s11894-009-0079-2","relation":{},"ISSN":["1522-8037","1534-312X"],"issn-type":[{"value":"1522-8037","type":"print"},{"value":"1534-312X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1,29]]}}}